Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans.
Veterans Health Administration
head and neck cancer
incidence
non-AIDS-defining cancers
people living with HIV/AIDS
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 09 2022
15 09 2022
Historique:
revised:
31
05
2022
received:
07
03
2022
accepted:
02
06
2022
pubmed:
23
7
2022
medline:
31
8
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
Persons living with HIV/AIDS have a higher incidence of virus-related and tobacco/alcohol-related cancers. This study is the first to estimate the effect of HIV versus HIV-negative veterans on the risk of head and neck squamous cell carcinoma incidence in a large retrospective cohort study. The authors constructed a retrospective cohort study using patient data from 1999 to 2016 from the National Veterans Administration Corporate Data Warehouse and the VA Central Cancer Registry. This cohort study included 45,052 veterans living with HIV/AIDS and 162,486 HIV-negative patients matched by age, sex, and index visit (i.e., HIV diagnosis date or clinic visit date). The age-standardized incidence rates and estimated adjusted hazard ratios were calculated with a Cox proportional hazards regression for oropharyngeal and nonoropharyngeal head and neck cancer squamous cell carcinoma (HNSCC). The authors also abstracted human papillomavirus (HPV) status from oropharyngeal HNSCC diagnosed after 2010. Veterans living with HIV/AIDS (VLWH) have 1.71 (95% confidence interval [CI], 1.36, 2.14) times the risk of oropharyngeal cancer and 2.06 (95% CI, 1.76, 2.42) times the hazard of nonoropharyngeal cancer compared with HIV-negative veterans. VLWH with oropharyngeal squamous cell carcinoma (OPSCC) were more likely to be HPV-positive (N = 30 [81.1%]) than the HIV-negative veterans with OPSCC (N = 50 [67.6%]), although this difference was not significant (p = .135). For nonoropharyngeal cancer, the increased risk of oral cavity cancer among VLWH drove the increased risk. The study results suggest that HIV may play a role in virally mediated and nonvirally mediated HNSCC. As the HIV prevalence rises in the United States due to better survival and the incidence of HPV-positive oropharyngeal HNSCC increases, the interaction between HPV and HIV becomes increasingly relevant.
Sections du résumé
BACKGROUND
Persons living with HIV/AIDS have a higher incidence of virus-related and tobacco/alcohol-related cancers. This study is the first to estimate the effect of HIV versus HIV-negative veterans on the risk of head and neck squamous cell carcinoma incidence in a large retrospective cohort study.
METHODS
The authors constructed a retrospective cohort study using patient data from 1999 to 2016 from the National Veterans Administration Corporate Data Warehouse and the VA Central Cancer Registry. This cohort study included 45,052 veterans living with HIV/AIDS and 162,486 HIV-negative patients matched by age, sex, and index visit (i.e., HIV diagnosis date or clinic visit date). The age-standardized incidence rates and estimated adjusted hazard ratios were calculated with a Cox proportional hazards regression for oropharyngeal and nonoropharyngeal head and neck cancer squamous cell carcinoma (HNSCC). The authors also abstracted human papillomavirus (HPV) status from oropharyngeal HNSCC diagnosed after 2010.
RESULTS
Veterans living with HIV/AIDS (VLWH) have 1.71 (95% confidence interval [CI], 1.36, 2.14) times the risk of oropharyngeal cancer and 2.06 (95% CI, 1.76, 2.42) times the hazard of nonoropharyngeal cancer compared with HIV-negative veterans. VLWH with oropharyngeal squamous cell carcinoma (OPSCC) were more likely to be HPV-positive (N = 30 [81.1%]) than the HIV-negative veterans with OPSCC (N = 50 [67.6%]), although this difference was not significant (p = .135). For nonoropharyngeal cancer, the increased risk of oral cavity cancer among VLWH drove the increased risk.
CONCLUSIONS
The study results suggest that HIV may play a role in virally mediated and nonvirally mediated HNSCC. As the HIV prevalence rises in the United States due to better survival and the incidence of HPV-positive oropharyngeal HNSCC increases, the interaction between HPV and HIV becomes increasingly relevant.
Identifiants
pubmed: 35867552
doi: 10.1002/cncr.34387
pmc: PMC10650941
mid: NIHMS1828869
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3310-3318Subventions
Organisme : NIMHD NIH HHS
ID : K01 MD013897
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI064518
Pays : United States
Organisme : CSRD VA
ID : I01 CX001430
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206476
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : CSRD VA
ID : IK2 CX001953
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Informations de copyright
© 2022 American Cancer Society.
Références
J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88
pubmed: 20841605
J Natl Cancer Inst. 2011 May 4;103(9):753-62
pubmed: 21483021
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819867354
pubmed: 31370775
J Clin Oncol. 2009 Feb 20;27(6):884-90
pubmed: 19114688
J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):e65-e72
pubmed: 30939533
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):122-33
pubmed: 22045700
PLoS One. 2013 Dec 18;8(12):e81355
pubmed: 24367482
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6
pubmed: 27387669
PLoS Pathog. 2018 Apr 13;14(4):e1006973
pubmed: 29652923
Clin Infect Dis. 2021 May 4;72(9):e224-e231
pubmed: 32710777
Oral Oncol. 2014 Dec;50(12):1169-76
pubmed: 25301563
Curr HIV/AIDS Rep. 2012 Sep;9(3):223-30
pubmed: 22618079
J Natl Cancer Inst. 2005 Mar 16;97(6):425-32
pubmed: 15770006
Curr Infect Dis Rep. 2018 May 26;20(8):22
pubmed: 29804238
AIDS. 2006 Aug 1;20(12):1645-54
pubmed: 16868446
Surg Oncol Clin N Am. 2015 Jul;24(3):379-96
pubmed: 25979389
Am J Epidemiol. 2013 Sep 15;178(6):885-7
pubmed: 23900552
Cancer. 2018 Jun 15;124(12):2515-2522
pubmed: 29645080
Cancer Med. 2020 Dec;9(24):9326-9335
pubmed: 33094910
Front Immunol. 2020 Oct 09;11:565683
pubmed: 33162980
JNCI Cancer Spectr. 2020 Jun 05;4(5):pkaa047
pubmed: 33225205
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
Oral Oncol. 2010 Jul;46(7):492-6
pubmed: 20227331
J Oral Pathol Med. 2018 Apr;47(4):396-402
pubmed: 29380908
J Clin Oncol. 2006 Mar 20;24(9):1383-8
pubmed: 16549832
Ann Intern Med. 2008 May 20;148(10):728-36
pubmed: 18490686
J Infect Dis. 2020 Jul 23;222(4):646-654
pubmed: 32211783
Am J Epidemiol. 2015 Jan 1;181(1):40-53
pubmed: 25480823
HIV Med. 2019 Sep;20(8):567-570
pubmed: 31131549